Danaher Joins Marble Center to Launch Anti-Cancer Nanomedicine Alliance
Danaher
Product Design and Manufacturer
Alloy Therapeutics
Drug Discovery and Development Service Provider
Fujifilm Holdings
Cross-border Imaging Technology and Product Developer
Sanofi
Pharmaceutical R&D Developer
Massachusetts Institute of Technology
The mission of the Massachusetts Institute of Technology is to advance knowledge and educate students in science, technology, and other areas of scholarship that will best serve the nation and the world in the 21st century.The Institute is committed to generating, disseminating, and preserving knowledge, and to working with others to bring this knowledge to bear on the world’s great challenges. It is dedicated to providing an education that combines rigorous academic study and the excitement of discovery with the support and intellectual stimulation of a diverse campus community. We seek to develop in each member of the Massachusetts Institute of Technology the ability and passion to work wisely, creatively, and effectively for the betterment of humankind.
ShanghaiJune 9, 2022PR Newswire -- Recently, the Marble Center for Cancer Nanomedicine -- established within the Koch Institute for Integrative Cancer Research at MIT -- announced the launch of a consortium initiative fostering collaboration between academia and industry. This initiative aims to drive breakthrough innovations across all fields impacted by nanomedicine, including drug delivery, gene editing, biomedical imaging, and diagnostics. The founding member companies of this initiative are Danaher Corporation, Alloy Therapeutics, Fujifilm Holdings Corporation, and Sanofi S.A.
Danaher Joins Marble Center Nanomedicine Industry Alliance Program to Jointly Advance Breakthrough Innovations in the Field of Nanomedicine.
Marble CenterNano Drug Industry AlliancePlan（IAMNano）It will provide its members with exclusive opportunities to participate in the research community and flagship programs of the Koch Institute, such as the Convergence Scholars Program, and create opportunities for formal scientific collaborations with member labs, accelerating the realization of biomedical innovations for clinical applications. The Marble Center will also establish an Industry Advisory Board to leverage its expertise in industry insights and business development.
Sangeeta N. Bhatia, a member of the Koch Institute, director of the Marble Center, and professor of health sciences and technology, electrical engineering, and computer science at MIT, stated: "For the past six years, our top priority has been to foster world-class research, accelerate scientific exchange and innovation, and invest in developing a diverse research community. The design of IAMNano has been guided by numerous discussions both within and outside of MIT, including input from an external review committee. We look forward to collaborating closely with new industry partners to establish the Marble Center as a hub in the field of nanomedicine and to support shaping the future of this field."
"As a leader in science and technology, Danaher understands the importance of investing in platform technologies that will one day play a critical role in delivering nucleic acid and cell therapies to patients. Danaher supports the production of cell and genomic medicines. Here, we are committed to advancing the best ideas – those that create products improving patients' lives," said Vanessa Almendro, head of Danaher’s innovation ecosystem. "Our collaboration with IAMNano reinforces our ambition to develop revolutionary technologies and nurture the next generation of nanomedicine scientific leaders."
AboutMarble CenterAnti-tumor NanomedicineGroup:
The Marble Center for Cancer Nanomedicine was established in 2016 thanks to a generous donation from Kathy and Curt Marble '63. It brings together a distinguished group of faculty members—Sangeeta Bhatia, Robert Langer, Paula Hammond, Daniel Anderson, Angela Belcher, and Darrell Irvine—and their teams at the Koch Institute for Integrative Cancer Research at MIT. Their mission is to address significant challenges in cancer detection, treatment, and monitoring, with a focus on miniaturization and convergence—integrating life sciences, natural sciences, and engineering technologies.